ArticleJMIR research protocols2025
Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNaltrexone is an opioid receptor antagonist. Naltrexone is used to block the euphoric and sedative effects of drugs such as heroin, codeine, and morphine. The medication helps to bind and block opioid receptors to decrease opioid cravings. In Malaysia, naltrexone has been used for maintenance treatments for heroin and alcohol since 1996. However, since 2011, naltrexone has been used as an off-label stimulant use disorder (StUD) treatment to achieve abstinence.
objectiveThis study aims to determine the abstinence among StUD and non-StUD patients treated and without naltrexone.
methodsWe will conduct a retrospective cohort study on the effect of naltrexone or treatment as usual (TAU) by examining the data for both StUD and non-StUD patients. We will use patients' clinical records from the hospital registry. All adult patients (aged 18-65 years) diagnosed with StUD or other substance use disorders who were treated with naltrexone and standard care from January 1, 2011, to December 31, 2023, will be screened. All StUD and non-StUD patients who were offered the naltrexone treatment or TAU at the beginning of treatment will be recruited. All data will be extracted using a standardized data extraction form. Descriptive analysis will be performed to describe the distribution of patient characteristics, sociodemographic profiles, and percentages of abstinence and treatment retention. We will conduct univariable analysis to determine the association of stimulant abstinence and treatment retention between naltrexone and TAU among both StUD and non-StUD patients. All significant independent variables will be further analyzed using a cross-sectional time series method for categorical variables.
resultsRecruitment began in July 2025. Data analysis will begin after completing data collection, planned for January 2026.
conclusionsThe expected main outcome of this study is to observe the significant associations of stimulant use abstinence and treatment retention between TAU and naltrexone among StUD and non-StUD patients. The findings from this study may provide preliminary evidence regarding the use of naltrexone in treating StUD. Currently, there is no specific medication to treat amphetamine or methamphetamine use disorder. The effect of naltrexone with psychosocial interventions for StUD is unclear. Public health approaches recognize the multifaceted nature of substance misuse and focus on addressing the myriad individual, environmental, and social factors that contribute to StUD. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/64101.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.